Company Profile

HESTER BIOSCIENCES LTD.

NSE : HESTERBIOBSE : 524669ISIN CODE : INE782E01017Industry : Pharmaceuticals & DrugsHouse : Private
BSE2428.65-37.85 (-1.53 % )
PREV CLOSE (Rs.) 2466.50
OPEN PRICE (Rs.) 2485.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 1304
TODAY'S LOW / HIGH (Rs.)2415.05 2497.65
52 WK LOW / HIGH (Rs.)1600 3180
NSE2432.40 -32.4 (-1.31 % )
PREV CLOSE(Rs.) 2464.80
OPEN PRICE (Rs.) 2499.00
BID PRICE (QTY) 2432.40 (243 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 30629
TODAY'S LOW / HIGH(Rs.) 2418.95 2500.00
52 WK LOW / HIGH (Rs.)1601 3134

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.41
TTM EPS (Rs.) 52.32
P/E Ratio 46.41
Book Value (Rs.) 293.67
Face Value (Rs.) 10
MCap (Rs. in Mn) 20660.20
Price/Earning (TTM) 38.20
Price/Sales (TTM) 9.06
Price/Book (MRQ) 8.27
PAT Margin (%) 19.14
ROCE (%) 23.28
Incorporation Year : 1987

Management Info :

Bhupendra V Gandhi - Chairman Rajiv Gandhi - Managing Director

Registered Office :

Address : Pushpak’ 1st Floor,Panchvati Circle,Motila Hirabhai Road,
Ahmedabad,
Gujarat-380006

Phone : 079 – 26445107

Email : mail@hester.in

Website : www.hester.in

Registrar's Details : Link Intime India Pvt Ltd.
506-508, 5th Floor, Amaranth Business Complex - I (ABC - I),Beside Gala Business Center, St. Xaviers Corner, Off C.G. Road,Navrangpura,Ahmedabad
Listing : BSE, NSE
NEWS More
28Oct10-28-2021$Hester Biosciences informs about outcome of board meeting Hester Biosciences informs a
Hester Biosciences has informed that Board of Directors, in its Meeting held today, have approved the followings: Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30 September 2021, as recommended by Audit Committee; Appointment of Priya Gandhi as a Whole-time Director of the Company for the period for 5 (Five) years, subject to approval of members; Appointment of Ameet Desai as an Independent Director of the Company for the period of 5 (Five) years, subject to approval of members. Also attached the approved standalone and consolidated unaudited financial results and limited review reports; and Press Release issued in this regard.

The above information is a part of company’s filings submitted to BSE.

Hester Biosciences has informed that Board of Directors, in its..
28Oct10-28-2021$Hester Biosciences informs about press release Hester Biosciences informs a
Hester Biosciences has informed that it enclosed press release titled 'Hester Biosciences Limited Q2 and H1 FY22 Results- Revenue up by 6% and 24%, Net Profit up by 16% and 35%, for Q2 and H1 FY22 - Appointment of additional Directors on the Board'.

The above information is a part of company’s filings submitted to BSE.

Hester Biosciences has informed that it enclosed press release..
22Oct10-22-2021$Hester Biosciences informs about earnings conference call Hester Biosciences informs a

Hester Biosciences has informed that as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has arranged earnings conference call on Thursday, 28 October 2021 at 2:00 pm (IST) to discuss the standalone and consolidated unaudited financial results for the quarter and half year ended 30 September 2021.

The above information is a part of company’s filings submitted to BSE.

Hester Biosciences has informed that as per Regulation 30 of SE..
30Sep09-30-2021$Hester Biosciences informs about closure of trading window Hester Biosciences informs a

Pursuant SEBI (Prohibition of Insider Trading) Regulations and the code of conduct of the Company to Regulate, Monitor and Report Trading by Directors, Promoters, Designated Employees and Specified Connected Persons of the Company and Material Subsidiaries of the Company, Hester Biosciences has informed that the ‘Trading Window’ for dealing in equity shares of the Company shall remain closed from 01.10.2021 and will end 48 hours after the financial results of the Company for the quarter ended 30.09.2021 become generally available as public information.

The above information is a part of company’s filings submitted to BSE.

Pursuant SEBI (Prohibition of Insider Trading) Regulations and..
12Aug08-12-2021$Hester Biosciences informs about outcome of board meeting Hester Biosciences informs a

With reference to its letter dated 04.08.2021 intimating the date of the Board Meeting for consideration of the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30.06.2021. Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Hester Biosciences has informed that that Board of Directors, in their Meeting held today, have approved the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30.06.2021, as recommended by Audit Committee. The company has attached: The approved standalone and consolidated unaudited financial results and limited review reports and press release issued in this regard. The company has published the extract of results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board Meeting commenced at 10:45 am (IST) and concluded at 11:03 am. (IST).

The above information is a part of company’s filings submitted to BSE.

With reference to its letter dated 04.08.2021 intimating the da..
Financials More
Rs. in Millions
QTR Sep 21 ANNUAL 21
Net Profit117.74399.01
Gross Profit 157.82 547.83
Operating Profit 184.57736.41
Net Sales 565.942084.77
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
SMS Lifesciences (BSE)
 998.75 (14.90%)
M.Cap ( in Cr)
301.95
Gland Pharma (BSE)
 3596.90 (2.06%)
M.Cap ( in Cr)
59097.74
Kwality Pharma (BSE)
 1057.45 (5.00%)
M.Cap ( in Cr)
1097.23
Ajanta Pharma (BSE)
 2127.80 (1.89%)
M.Cap ( in Cr)
18413.08
ANG Lifesciences (BSE)
 569.35 (5.00%)
M.Cap ( in Cr)
590.22
Shareholding Pattern More
PROMOTERS 53.73 %
NON-INSTITUTION 45.58 %
FI/BANKS/INSURANCE 0 %
MUTUAL FUNDS/UTI 0 %
GOVERNMENT 0 %
FII 0 %
MF HOLDINGS More
Scheme NameHold(%)
ITI Small Cap Fund-Reg(G)2.20
F & O Quotes